Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (15,760,741)	$ (7,980,831)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	58,219	20,282
Change in fair value of warrant liability	(2,045,082)	(2,328,298)
Financing expense	142,788	88,939
Stock-based compensation	759,424	666,123
Restricted stock issued for services	0	9,400
Accrued interest on CIRM award	889,146	0
Changes in assets and liabilities:
Other assets	166,200	(354,142)
Supplies for clinical trials	(377,837)	0
Deposits	655,395	(4,060,977)
Accounts payable	(764,613)	535,594
Accrued compensation and benefits	(431,268)	153,690
Accrued liabilities	584,920	26,449
Net cash used in operating activities	(16,123,449)	(13,223,771)
Cash flows from investing activities:
Purchase of property and equipment	(4,015)	(169,750)
Net cash used in investing activities	(4,015)	(169,750)
Cash flows from financing activities:
Proceeds from the issuance of common stock through controlled equity offering	691,187	0
Proceeds from CIRM award	1,500,000	0
Proceeds from issuance of common stock and warrants net of offering costs	6,629,619	14,606,377
Net cash provided by financing activities	8,820,806	14,606,377
(Decrease) increase in cash and cash equivalents	(7,306,658)	1,212,856
Cash and cash equivalents, beginning of period	22,604,481	23,222,296
Cash and cash equivalents, end of period	15,297,823	24,435,152
Supplemental cash flows disclosures:
Interest expense paid	0	0
Income taxes paid	0	0
Supplemental non-cash disclosures
Financing costs included in accounts payable	$ 75,000	$ 0